問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberDB-1311-201
Active

2025-09-01 - 2030-06-30

Recruiting7

ICD-10C7A.1

Malignant poorly differentiated neuroendocrine tumors

ICD-10C7A.8

Other malignant neuroendocrine tumors

ICD-10C7B.09

Secondary carcinoid tumors of other sites

ICD-10C7B.1

Secondary Merkel cell carcinoma

ICD-10C7B.8

Other secondary neuroendocrine tumors

ICD-10C80.0

Disseminated malignant neoplasm, unspecified

ICD-10D3A.8

Other benign neuroendocrine tumors

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9199.0

Disseminated malignant neoplasm

  • Trial Applicant

    PAREXEL INTERNATIONAL CO., LTD.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/04/01

Investigators and Locations

Principal Investigator ZHENG-WEI ZHOU Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Sheng-Shun Yang Division of General Internal Medicine

Co-Principal Investigator

  • 柯萬盛 Division of General Internal Medicine

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chia-Chi Lin Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 張志隆 Division of Obstetrics & Gynecology

Co-Principal Investigator

  • 王功亮 Division of Obstetrics & Gynecology
  • 詹雅婷 Division of Obstetrics & Gynecology
  • 陳楨瑞 Division of Obstetrics & Gynecology

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Shau-Hsuan Li Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Wei-Hong Cheng Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Muh-Hwa Yang Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    49 participants

  • Global

    492 participants